India, June 23 -- Teleflex Incorporated (TFX), a medical technology company, on Tuesday announced initiation of enrollment in the BIOMAG-III IDE trial for Freesolve Resorbable Magnesium Absorbable Scaffolds in treating damaged blood vessels.
The Freesolve Resorbable Magnesium Scaffold (RMS) was developed as an alternative to metallic stents, as the scaffold supporting the damaged blood vessel is resorbed over time to prevent immunogenic reactions. The RMS was designed to resorb within 12 months, reducing the likelihood of long-term events associated with traditional stents.
BIOMAG-III is a pivotal, randomized controlled trial (RCT) that plans to enroll 1859 patients across 120 sites worldwide. The study will utilise scaffolds up to 40 mm ...